Mandate

Vinge has advised Industrifonden and Investinor in connection with a sale of shares in Calliditas

Vinge has advised Industrifonden and Investinor in connection with a sale of in total approximately 2,300,000 shares in Calliditas Therapeutics AB (publ) to two investors for a total value of approximately USD 17,000,000.

Calliditas is listed on Nasdaq Stockholm and focuses on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which the company can partially or completely participate in the commercialization efforts.

Vinge’s team consisted of Dain Hård Nevonen, Sofie Bjärtun, Nils Fredrik Dehlin and Hampus Olsson.

Related

Vinge advises Ambea on the acquisition of Validia

Vinge has acted as advisor to Ambea AB (publ) together with the Finnish law firm Krogerus in connection with the acquisition of Validia Oy from Invalidiliitto, the Finnish Association for the Disabled, a leading care provider in Finland. Through the acquisition, Ambea establishes a presence in the Finnish market and strengthens its position as the only care provider with operations in the four largest Nordic countries. The purchase price amounts to a total of SEK 1, 382 million.
March 12, 2025

Vinge advises on the sale of Road Rental

Vinge has advised Sobro and other shareholders in connection with the sale of Road Rental to BUKO Group, a leading European actor within temporary traffic management solutions. This strategic partner will give Road Rental access to a broad international network, strong resources and expertise which will enable continued expansion in Sweden as well as the rest of Scandinavia.
March 12, 2025

Vinge has advised Röko in connection with its listing on Nasdaq Stockholm

Vinge has advised Röko AB (publ) (“Röko”) in connection with its listing on Nasdaq Stockholm. The prospectus was published on March 4, 2025 and the first day of trading is March 11, 2025.
March 11, 2025